《大行報告》野村下調泰格醫藥(03347.HK)目標價至115.13元 評級「買入」
野村發表報告指,泰格醫藥(03347.HK)今年首季收入按年增102%至18億元人民幣。
該行表示,考慮到近期上海新冠疫情及對其國內CRO臨牀試驗全過程專業服務業務影響,將公司今年及明年收入預測微調下降1%及4%;將公司今年及明年的盈利預測下調8%及10%,以反映較低支出但同時較低的非經常性收入。
該行將其目標價由134.75元下調至115.13元,維持其「買入」評級,以考慮到公司在快速增長的CRO領域的領先地位。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.